If the incorporation of new technologies and more efficient methods is a common practice in all fields of science, it has been precisely in the study of proteins where the innovation has achieved impressive proportions. Each year biotechnology graduates from community colleges to universities across the globe make excellent contributions to the biotechnology industry.
Biotechnology is now considered a converging technology that includes nanotechnology, information sciences, and cognition, leading to massive changes in the nature of instrumentation, analysis, and manufacturing processes. Biotechnology is a green and human-scale technology. It will become our major technology if mankind has any future, and today we are only seeing its very beginnings.
Biotechnologically-derived drugs (biotech drugs) including proteins, peptides, monoclonal antibodies and antibody fragments, as well as antisense oligonucleotides and DNA preparations for gene therapy, have been a major focus of research and development (R&D) efforts in the pharmaceutical industry and biotech drugs constitute already a sizable fraction of the medications used in clinical practice. By 2014, it is predicted that five of the top 10 products in the global pharmaceutical market will be antibodies along with two other recombinant protein products.